Portola Pharma (PTLA) Misses Q2 EPS by 24c, Miss on Revenues

Portola Pharma (NASDAQ: PTLA) reported Q2 EPS of ($1.22), $0.24 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $3.79 million versus the consensus estimate of $8.84 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c